This position statement outlines the management of patients with concurrent T2DM and heart failure, emphasizing the safety and efficacy of standard HF therapies and the benefit of SGLT2 inhibitors.
No takes yet. Share an insight, caveat, or question.
Recommend SGLT2 inhibitors and avoid thiazolidinediones in T2DM with or at HF risk; extends RCT data into clinical guidance.
Seferović et al. (2018) conducted a review in Type 2 Diabetes Mellitus and Heart Failure. A position statement highlighting that SGLT2 inhibitors reduce heart failure hospitalization in patients with or at risk of cardiovascular disease, while thiazolidinediones are contraindicated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: